Drug Discovery World: The Impact of ADCs on Drug Discovery E-Book

Antibody-drug conjugates (ADCs) offer a targeted approach to cancer treatment, combining the specificity of antibodies with the potency of cytotoxic drugs, and have shown promise in improving patient outcomes.

In our latest e-book with Drug Discovery World, we explore the recent developments in the ADC field and the opportunities presented by next-generation bioconjugates.

Download this exclusive eBook to learn more about:

• How targeted therapies can reduce cancer side effects
• The challenges in solid tumor targeting with bispecific ADCs
• The future potential for ADCs
• The rise of the bioconjugates

Access the E-Book

Abzena’s ADC Expertise

With over two decades of expertise, 2000+ conjugates development and 3000+ linker-payloads designed, our team has the scientific know-how and technical skills to help you progress your bioconjugates from early R&D through commercial supply. Our site-specific conjugation technology, ThioBridge, has been proven to enhance the potency, safety, and efficacy of ADCs, offering a de-risked and streamlined solution.  Click here to learn more about our extensive and fully integrated capabilities to support bioconjugates.